<DOC>
	<DOCNO>NCT00382096</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety fix combination vildagliptin metformin lower blood glucose patient type 2 diabetes</brief_summary>
	<brief_title>Efficacy Fixed Combination Therapy Vildagliptin Metformin Compared Individual Monotherapy Components Drug Naive Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female ( nonfertile childbearing potential use medically approve birth control method ) patient type 2 diabetes Diagnosis T2DM least 4 week prior study entry Age 18 78 year inclusive Body mass index ( BMI ) 22 40 kg/m2 HbA1c : 7.5 11 % inclusive FPG &lt; 270 mg/dL ( 15 mmol/L ) Exclusion Criteria Pregnant lactate female A history type 1 diabetes Evidence significant diabetic complication Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>metformin</keyword>
	<keyword>hemoglobin A1c</keyword>
</DOC>